Share on LinkedInShare on LinkedIn

ARTICLE · 13 DECEMBER 2017

Inherent Obviousness: Available IPR Rationale With A High Standard

Jones Day
Jones Day
Contributor
Jones Day

Jones Day

Jones Day is a global law firm with more than 2,400 lawyers in 40 offices across five continents....

View firm profile
Explore more from Jones Day

On November 28, 2017, the PTAB issued a final written decision upholding the patentability of U.S. Patent No. 6,667,061 (IPR2016-01096).

United StatesIntellectual Property

On November 28, 2017, the PTAB issued a final written decision upholding the patentability of U.S. Patent No. 6,667,061 (IPR2016-01096).  The '061 patent is owned by Alkermes Pharma Ireland, Ltd. and Alkermes Controlled Therapeutics, Inc. ("Alkermes"), and is listed in the Orange Book in connection with formulations of risperidone (Janssen Pharmaceuticals, Inc.) and naltrexone (Alkermes, Inc.), as well as several formulations by AstraZeneca AB (exenatide, synthetic exenatide, and dapagliflozin propanediol).  Luye Pharma Group Ltd. ("Luye") challenged several of the claims on various obviousness grounds, including assertions of the inherent properties of prior art formulations.  Our previous report on the PTAB's decision to institute this IPR can be found here.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from